Apeloa pharma signs strategic partnership with anticon biotech for drug development

Apeloa Pharmaceutical recently announced a strategic cooperation framework agreement with Jiaxing Anticon Biotech. This agreement establishes a long-term partnership focused on innovative drug development and contract development and manufacturing organization (CDMO) services. The goal is to enhance industry competitiveness and ensure a stable supply chain for pharmaceutical products. While specific project agreements will follow, Apeloa Pharmaceutical will prioritize providing CDMO research and production services to Anticon Biotech.

The framework agreement is valid for ten years and is not expected to significantly impact Apeloa Pharmaceutical's operating performance for the current year. However, successful implementation of future specific business collaborations could positively influence the company's operating results in subsequent years.

This strategic collaboration aligns with Apeloa Pharmaceutical's efforts to expand its CDMO business. The company has previously entered into similar framework agreements with other entities, including Jiangsu Hansoh Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, and Shanghai RemeGen Biotechnology, all of which are currently being fulfilled.